STORM Therapeutics

Stub active Updated Apr 16, 2026

This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.

Location Cambridge, United Kingdom
Latest Stage Series C
Total Raised $56M+
Sector
biotech oncology

Founders

Jerry McMahon CEO

About

STORM Therapeutics is a Cambridge, UK-based clinical-stage biotechnology company targeting RNA modifications to reprogram cells and develop novel cancer therapies 1. The company’s lead program is STC-15, a first-in-class oral small-molecule inhibitor of METTL3, which has demonstrated durable tumor regression across multiple sarcoma subtypes in Phase 1 1.

Funding History

Date Round Amount Lead Co-investors
2026-04-16 Series C $56M — M Ventures, Pfizer Ventures, Taiho Ventures, IP Group, UTokyo IPC, Fast Track Initiative 1

What Investors Say

No verified investor quotes available at this time.

What Founders Say

No verified founder quotes available at this time.

Sources

  1. GlobeNewsWire, “STORM Therapeutics Secures $56 Million Series C Financing and Doses First Patient in Phase 2 Sarcoma Trial of STC-15,” April 16, 2026. https://www.globenewswire.com/news-release/2026/04/16/3275048/0/en/STORM-Therapeutics-Secures-56-Million-Series-C-Financing-and-Doses-First-Patient-in-Phase-2-Sarcoma-Trial-of-STC-15.html↩↩↩